Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-07-30
1999-01-12
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
4241901, 4242401, 530350, 530825, A61K 3816, A61K 3910
Patent
active
058589651
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention is generally in the field of agents that may be used for the treatment of autoimmune diseases, and more particularly relates to pharmaceutical compositions comprising the B-oligomer of pertussis toxin or one of its subunits S2, S3, S4 or S5, or combinations thereof, useful for protection against autoimmune diseases.
BACKGROUND OF THE INVENTION
The gram-negative bacterium Bordetella pertussis (B. pertussis), the causative agent of whooping cough, produces several virulence factors. Pertussis toxin (PT), the major virulence component of B. pertussis, appears to contain an important epitope that leads to the formation of antibodies capable of protecting against the disease. Therefore, PT has been extensively investigated with regard to its possible use in preparing vaccines for whooping cough (Black et al., 1988).
Pertussis toxin is a 105-kDa hexameric protein composed of five distinct non-covalently linked polypeprides designated (in the order of decreasing molecular weight) S1-S5.PT can be divided into two distinct functional units, the enzymatically active toxic A-protomer, consisting of a single polypeptide (S1), and the pentameric B-oligomer (S2, S3, two copies of S4, and S5, i.e. molar ratiol:1:2:1). The B-oligomer is responsible for binding of the toxin to the surface of eukaryotic target cells. The two S4 polypeptides form two distinct heterodimers with S2 and S3, which are in turn held together by S5 (see review by Gierschik, 1992).
The perrussis toxin gene has been cloned and sequenced (Nicosia et al., 1986; European Patent Application EP 0232 229; Locht and Keith, 1986; U.S. Pat. No. 4, 883,761). The individual subunits have been subcloned and expressed in E. coli in nonfusion form (Burnette et al.,1988) or as fusion proteins (Nicosia et al., 1987), and tested as antigens for protection against whooping cough.
The development of experimental autoimmune encephalomyelitis (EAE), as well as other autoimmune diseases in experimental animals, can be facilitated by injecting Bordetella pertussis concomitantly with inoculation of the autoantigen (Bernard et al., 1992). EAE is a neurological autoimmune disease which can be induced in experimental animals by a single injection of central nervous system (CNS) tissue homogenate or purified myelin antigens such as myelin basic protein (MBP) or proteolipid protein (PLP) in complete Freund's adjuvant (CFA) (Tabira and Kira, 1992). The clinical and pathological features of EAE are reminiscent of multiple sclerosis , and EAE is a well-accepted model for multiple sclerosis. In mice,. consistent elicitation of EAE was shows to be facilitated by administration of B. pertussis at the time of the encephalitogenic challenge (Munoz, 1985). Pertussis toxin (PT) was shown later to be the component of B. pertussis responsible for facilitating disease development, and it is now routinely used in place of B. pertussis for enhancement of autoimmune disease in experimental animals (Munoz, 1995).
In an analysis of the possible inununomodulating activity of various bacteria, it was found by the present inventor that B. pertussis not only enhances the development of EAE in mice, but can also protect against the disease depending on the time and route of injection (Lehman and Ben-Bun, 1993). The protective activity of B. pertussis was subsequently assigned to PT (Ben-Nun et al., 1993).
Pertussis toxin (PT), the major virulence determinant of B. pertussis , is composed of two distinct functional units: the A-protomer consisting of a single polypeptide (S1) that mediates adenosine diphosphate (ADP)-ribosylation of host G proteins, and the B-oligomer, a complex pentamer composed of subunits S2, S3, S4 and S5 in a respective molar ratio of 1:1:2:1, which mediates the binding of the toxin to host tissue by interaction with glycoproteins and glycolipids on many types of eukaryotic cells (Gierschik, 1992). PT was found to have mitogenic and immunoadjuvant properties (Munoz, 1985). The mechanism by which PT can enhance the development of EAE
REFERENCES:
patent: 4845036 (1989-07-01), Burns et al.
patent: 5453272 (1995-09-01), Heerze et al.
Nencioni et al., "Properties of the B Oligomer of Pertussis Toxin,", Infection And Immunity, vol. 59, No. 12, pp. 4732-4734 (Dec. 1991).
Tamura et al., "A Role of the B-Oligomer Moiety of Islet-activating Protein, Pertussis Toxin, in development of the Biological Effects on Intact Cells." THE Journal Of Biological Chemistry, vol. 258, No. 11, pp. 6756-6761 (10 Jun. 1983).
Ben-Nun et al., "Protection Against Autoimmune Disease by Bacterial Agents II. PPD and Pertussis Toxin as Proteins Active in Protecting Mice Against Expiramental Autoimmune Encephalomyelitis." Eur. J. Immunol., vol. 23, No. 3, pp. 689-696 (1993).
W.J. Black et al., "ADP-Ribosyltransferase Activity of Pertussis Toxin and Immunomodulation by Bordetella Pertussis", Science, vol. 240, pp. 656-659, Apr. 29, 1988.
W. Neal Burnette et al., "Direct Expression of Bordetella Pertussis Toxin Subunits to High Levels in Escherichia Coli", Bio/Technology, vol. 6, pp. 699-706, Jun., 1988.
Drusilla L. Burns et al., "Role of the A Subunit of Pertussis Toxin in Alteration of Chinese Hamster Ovary Cell Morphology", Infection and Immunity, vol. 55, No. 1, pp. 24-28, Jan., 1987.
P. Gierschik, "Guanine Nucleotide-Binding Proteins by Pertussis Toxin", Current Topics in Microbiology and Immunology, vol. 175, pp. 69-96, 1992.
Dan Lehmann et al., "Bacterial Agents Protect Against Autoimmune Disease. I. Mice Pre-Exposed to Bordetella Pertussis or Mycobacterium Tuberculosis are Highly Refractory to Induction of Experimental Autoimmune Encephalomyelitis", Journal of Autoimmunity, vol. 5, pp. 675-690, 1992.
D. Scott Linthicum et al., "Acute Experimental Autoimmune Encephalomyelitis in Mice", Cellular Immunology, vol. 73, pp. 299-310, 1982.
Camille Locht et al., "Pertussis Toxin Gene: Nucleotide Sequence and Genetic Organization", Science, vol. 232, pp. 1258-1264, 1986.
Alfredo Nicosia et al., "Cloning and Sequencing of the Pertussis Toxin genes: Operon Stucture and Gene Duplication", Proc. Natl. Acad. Sci. USA, vol. 83, pp. 4631-4635, Jul. 1986.
A. Nicosia et al., "Expression and Immunological Properties of the Five Subunits of Pertussis Toxin", Infection and Immunity, vol. 55, pp. 963-967, Apr. 1987.
Makoto Tamura et al., "Subunit Structure of Islet-Activating Protein, Pertussis Toxin, in Conformity with the A-B Model", Biochemistry, vol. 21, pp. 5516-5522, 1982.
Russel Jeffrey E.
Yeda Research and Development Co. Ltd.
LandOfFree
Pharmaceutical compositions for the treatment of autoimmune dise does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions for the treatment of autoimmune dise, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for the treatment of autoimmune dise will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1515869